AI Product

BostonGene — Biotechnology

AI foundation model integrating genomic, transcriptomic, immune, and clinical signals for tumor portraits, biomarker discovery, trial optimization, and precision therapy…

Intelligence Summary

Product
  • Active
  • Verified public sources
  • Developer BostonGene
  • Category Biotechnology
  • Status Active
  • Latest update 2015: BostonGene founded in Waltham, Massachusetts.
  • Documentation Official page
  • Last reviewed Jul 2026
6 Technologies

Official product page

Target customer

Pharmaceutical R&D teams, biotech sponsors, and academic cancer centers seeking multimodal AI for patient selection, trial design, and companion biomarker strategies.

Features & capabilities

Industries: AI in Healthcare; Biotechnology

Related reports

Related insights

Overview

AI foundation model integrating genomic, transcriptomic, immune, and clinical signals for tumor portraits, biomarker discovery, trial optimization, and precision therapy decisions across oncology and immune-mediated diseases.

Product and company

BostonGene — Biotechnology is a verified product offering linked to the Brel Digital company profile for BostonGene.

Use cases

AI foundation model integrating genomic, transcriptomic, immune, and clinical signals for tumor portraits, biomarker discovery, trial optimization, and precision therapy decisions across oncology and immune-mediated diseases.

Target customer

Pharmaceutical R&D teams, biotech sponsors, and academic cancer centers seeking multimodal AI for patient selection, trial design, and companion biomarker strategies.

Technologies

Primary technologies assigned from the linked company profile: AI Governance, Deep Learning, Healthcare Analytics, Large Language Models, Machine Learning, Predictive Analytics.

Sources and references

  • Official product / company source: https://bostongene.com/news-and-publications/news/bostongene-receives-frost-and-sullivan-s-2026-global-company-of-the-year-for-advancing-in-ai-driven-multimodal-oncology-platforms
  • Supporting source: https://bostongene.com/news-and-publications/news/bostongene-ceo-andrew-feinberg-to-deliver-keynote-at-mobile-world-congress-barcelona-2026

Product facts are limited to information already verified on the linked Brel company profile and its cited official URLs. No speculative capabilities are added.

Last reviewed

This product profile was last reviewed on 2026-07-14.

Correction request

If this product record is inaccurate or outdated, submit a correction through Brel Digital’s Corrections Policy.

Features and capabilities

  • AI foundation model integrating genomic, transcriptomic, immune, and clinical signals for tumor portraits, biomarker discovery, trial optimization, and precision therapy decisions across oncology and immune-mediated diseases.

Extracted from the linked company product description already verified on Brel. No capabilities were invented.

Sources and references

This article draws on publicly available company information, official websites, filings, interviews, announcements, and other cited sources. Information may change over time.

Enquire about this product profile

Messages are delivered to contact@breldigital.com.